SystImmune, Inc. announces FDA clearance of IND application for BL-M11D1 in relapsed/refractory Acute Myeloid Leukemia

BlissBio receives IND approval from FDA for novel ADC BB-1712

ENHERTU approved in China as first HER2 directed therapy for patients with HER2 mutant metastatic...